Treatment News : Many People on Therapy for HIV Should Qualify for Life Insurance

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » April 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


April 1, 2013

Many People on Therapy for HIV Should Qualify for Life Insurance

Thanks to the success of modern antiretrovirals (ARVs), many people with HIV on successful treatment have a low enough mortality risk to qualify for life insurance, a group of European researchers argue. Currently, life insurance policies are largely unavailable to people living with HIV. Seeking to determine how HIV-positive people would fare on an actuarial scale, the investigators studied adults from the European Antiretroviral Therapy Cohort Collaboration (ART-CC) and published their findings in the journal AIDS.

The study analyzed data from about 35,000 people who began ARVs between 1996 and 2008. Seventy percent of the group were males between the ages of 30 and 49, and three-quarters had a CD4 count below 350 when they began treatment. None had been infected with HIV as a result of injection drug use, nor were any living with hepatitis C virus (HCV) at the beginning of the study.

During the 174,906 person-years of follow-up, there were 1,236 deaths among the group, for a mortality rate of 0.71 per 100 person-years of follow-up. Comparing the insured HIV-negative general population with the lowest risk group in the study cohort—those with undetectable viral load and CD4s above 350—the investigators found that adults in this subgroup who were in their 30s had a 459 percent relative mortality risk to the HIV-negative population comparison group. This rate is within the cut-off of 500 percent that life insurance companies typically use to determine insurability.

The mortality risk dropped lower for older people in the cohort and for those on therapy for longer. Members of the group in their 40s with a CD4 count between 200 and 340 who had been on therapy for over seven years had a relative mortality risk of 238 percent. On average, 61 percent of those on ARVs had a mortality risk below 500 percent, and 28 percent had a risk lower than 300.

To read the abstract, click here.

To read the aidsmap story, click here.

Search: life insurance, HIV, mortality risk, Antiretroviral Therapy Cohort Collaboration, ART-CC, AIDS, antiretrovirals, undetectable viral load, CD4.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.